Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 23 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 23 4.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 23.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Hypertonic sodium chloride solution increases plasma osmolality, drawing water from intracellular to extracellular space, expanding intravascular volume, and promoting diuresis. It also provides sodium and chloride ions for electrolyte replenishment.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Severe hyponatremia: 100-150 mL of 23.4% sodium chloride (27-40 g NaCl) IV over 1-2 hours via central line; maximum rate 1-2 mL/min. Repeat dose based on serum sodium levels. Not for direct IV push; must be diluted or used via central line.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable as sodium chloride is an electrolyte; distribution and elimination follow body sodium homeostasis, with renal regulation having a half-life of hours to days depending on volume status.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >95% as sodium and chloride ions; negligible biliary/fecal.
Category C
Category A/B
Electrolyte
Electrolyte